Selected publications:-

 • Bone and Soft-Tissue Sarcomas


The hypoxia marker CAIX is prognostic in the UK phase III VorteX-Biobank cohort: an important resource for translational research in soft tissue sarcoma. Forker L, Gaunt P, Sioletic S, Shenjere P, Potter R, Roberts D, Irlam J, Valentine H, Hughes D, Hughes A, Billingham L, Grimer R, Seddon B, Choudhury A, Robinson M, West CML. Br J Cancer. In press


The protective role of sphingosine-1-phosphate against the action of the vascular disrupting agent combretastatin A-4 3-O-phosphate. Shepherd J, Fisher M, Welford A, McDonald DM, Kanthou C, Tozer GM. Oncotarget. 2017;8(56):95648-95661.

Zebrafish xenograft models of cancer and metastasis for drug discovery. Brown HK, Schiavone K, Tazzyman S, Heymann D, Chico TJ. Expert Opin Drug Discov. 2017;12(4):379-389.


Establishment and molecular characterisation of seven novel soft-tissue sarcoma cell lines. Salawu A, Fernando M, Hughes D, Reed MW, Woll P, Greaves C, Day C, Alhajimohammed M, Sisley K. Br J Cancer. 2016, 115(9):1058-1068.

Tumour heterogeneity: the key advantages of single-cells analysis. Tellez-Gabriel M, Ory B, Lamoureux F, Heymann MF, Heymann D. Int J Mol Sci 2016, 17, 2142.

The challenges of detecting circulating tumour cells in sarcoma. Tellez-Gabriel M, Brown HK, Young R, Heymann MF, Heymann D. Frontiers in Oncol, 2016, 6:202.

Circulating tumor cells: a review of non EpCAM-based approaches for cell enrichment and isolation. Tellez Gabriel M, Rodriguez Calleja L, Chalopin A, Ory B, Heymann D. Clin Chem 2016;62(4):571-81.

RANK-RANKL signalling in cancer. Renema N, Navet B, Heymann MF, Lezot F, Heymann D. Biosci Rep, 2016;36(4). pii: e00366.


MALDI-MSI and label-free LC-ESI-MS/MS shotgun proteomics to investigate protein induction in a murine fibrosarcoma model following treatment with a vascular disrupting agent. Cole LM, Bluff JE, Carolan VA, Paley MN, Tozer GM, Clench MR. Proteomics. 2014;14 (7-8):890-903.

A system for accurate and automated injection of hyperpolarized substrate with minimal dead time and scalable volumes over a large range. Reynolds S, Bucur A, Port M, Alizadeh T, Kazan SM, Tozer GM, Paley MN. J Magn Reson. 2014; 239:1-8

• Bone Sarcoma

Paradoxical side effects of bisphosphonates on the skeleton: what do we know and what can we do? Franco JWV, Castaneda BH, Redini F, Gomez DF, Heymann D, Lezot FPR. J Cell Physiol. In press

The contribution of immune infiltrates and the local microenvironment in the pathogenesis of osteosarcoma. Heymann MF, Lézot F, Heymann D. Cell Immunol. In press


Cx43 intercellular communication drives the early differentiation of human bone marrow stromal cells into osteoblasts. Talbot J, Brion R, Lamora A, Morice S, Heymann D, Verrecchia F. J Cell Physiol. 2018, 233(2):946-957

Biology of Bone Sarcomas and New Therapeutic Developments. Brown HK, Schiavone K, Gouin F, Heymann MF, Heymann D. Calcif Tissue Int. 2018,102(2):174-195.


Bone microenvironment has an influence on the histological response of osteosarcoma to chemotherapy: retrospective analysis and preclinical modeling. Crenn V, Biteau K, Amiaud J, Dumars C, Guiho R, Vidal L, Le Nail LR, Heymann D, Moreau A, Gouin F, Redini F. Am J Cancer Res. 2017, 7(11):2333-2349.

Cancer stem cells in osteosarcoma. Brown HK, Tellez-Gabriel M, Heymann D. Cancer Lett. 2017;386:189-195.

Osteoprotegerin regulates cancer cell migration through SDF-1/CXCR4 axis and promotes tumour development by increasing neovascularization. Benslimane-Ahmim Z, Pereira J, Lokajczyk A, Dizier B, Galy-Fauroux I, Fischer AM, Heymann D, Boisson-Vidal C. Cancer Lett. 2017;395:11-19.

Analysis of gap junctional intercellular communications using a dielectrophoresis-based microchip. Tellez-Gabriel M, Charrier C, Brounais-Le Royer B, Mullard M, Brown HK, Verrecchia F, Heymann D. Eur J Cell Biol. 2017;96(2):110-118.

Low-Dose Pesticide Mixture Induces Senescence in Normal Mesenchymal Stem Cells (MSC) and Promotes Tumorigenic Phenotype in Premalignant MSC. Hochane M, Trichet V, Pecqueur C, Avril P, Oliver L, Denis J, Brion R, Amiaud J, Pineau A, Naveilhan P, Heymann D, Vallette FM, Olivier C. Stem Cells. 2017 ; 35(3):800-811.

Inhibition of BET proteins and epigenetic signaling as a potential treatment for osteoporosis. Baud'huin M, Lamoureux F, Jacques C, Rodriguez Calleja L, Quillard T, Charrier C, Amiaud J, Berreur M, Brounais-LeRoyer B, Owen R, Reilly GC, Bradner JE, Heymann D, Ory B. Bone. 2017;94:10-21.


Dysregulation of macrophage polarization is associated with the metastatic process in osteosarcoma. Dumars C, Nguyen JM, Gaultier A, Lanel R, Corradini N, Gouin F, Heymann D, Heymann MF. Oncotarget, 2016, 78343-78354

Drugs in early clinical development for the treatment of osteosarcoma. Heymann MF, Brown HK, Heymann D. Expert Opin Invest Drugs, 2016, 25 :1265-1280.

miRNA-193a-5p repression of p73 controls cisplatin chemoresistance in primary bone tumors. Jacques C, Rodriguez-Calleja L, Baud’huin M, Quillard T, Heymann D, Lamoureux F, Ory B. Oncotarget, 2016, 7 : 54503-54514.

Targeting the epigenetic readers in Ewing sarcoma inhibits the oncogenic transciption factor EWS/FLi1. Jacques C , Lamoureux F, Baud'huin M , Rodriguez Calleja L , Quillard T, Amiaud J, Perrot P, Tirode F, Redini F , Bradner J , Heymann D, Ory B. Oncotarget, 2016, 7 :125-140.

TRAIL delivered by mesenchymal stromal/stem cells counteracts tumor development in orthotopic Ewing sarcoma models. Guiho R, Biteau K, Grisendi G, Taurelle J, Chatelais M, Gantier M, Heymann D, Dominici M, Redini F. Int J Cancer, 2016, 139 :1265-1280

Blocking HSP90 addiction inhibits tumor cell proliferation, metastasis development and synergistically acts with zoledronic acid to delay osteosarcoma progression. Ory B, Baud’huin M, Verrecchia F, Brounais-Le Royer B, Quillard T, Amiaud J, Battaglia S, Heymann D, Redini F, Lamoureux F. Clin Cancer Res, 2016, 22 : 2520-2533.

Np63a stimulates TGF-induced metastasis through microRNA regulation. Rodriguez Calleja L, Jacques, C, Lamoureux F, Baud’huin M, Tellez Gabriel M, Quillard T, Debashish S, Lecanda F, Verrecchia F, Heymann D, Ory B, Ellisen LW. Cancer Res 2016; 76(11):3236-51

L-MTP-PE and zoledronic acid combination in osteosarcoma: preclinical evidence of positive therapeutic combination for clinical transfer. Biteau K, Guiho R, Chatelais M, Taurelle J, Chesneau J, Corradini N, Heymann D, Redini F. Am J Cancer Res 2016;6(3):677-89.

Opposite effects of soluble factors secreted by adipose tissue on proliferating and quiescent osteosarcoma cells. Perrot P, Avril P, Ridel P, Heymann MF, De Pinieux G, Rédini F, Blanchard F, Heymann D, Trichet V. Plastic and reconstructive Surgery, 2016, 137(3) :865-875.215.

Anti-metastatic properties of a marine bacterial exopolysaccharide-based derivative designed to mimic glycosaminoglycans. Heymann D, Ruiz-Velasco C, Chesneau J, Ratiskol, Sinquin C, Colliec-Joault. Molecule 2016, 21(3) pii:309.

Mesenchymal stem cells increase proliferation but not change quiescent state of osteosarcoma cells : potential implications accoring to the tumor resection status. Avril P, Le Nail LR, Brennan M, Rosset P, De Pinieux G, Layrolle P, Heymann D, Perrot P, Trichet V. J Bone Oncol, 2016, 5:5-14.


Bone tumor environment as a potential therapeutic target in Ewing sarcoma. Redini F, Heymann D. Frontiers Oncol 2015 ; 5 :279.

Interleukin-34 promotes tumor progression and metastatic process in osteosarcoma through induction of angiogenesis and macrophage recruitment. Ségaliny AI, Mohamadi A, Dizier B, Lokajczyk A, Brion R, Lanel R, Amiaud J, Charrier C, Boisson-Vidal C, Heymann D. Int J Cancer. 2015;137 (1):73-85

Primary Hepatic Ewing Sarcoma With EWS-FLI1 RNA Transcript in a Child. Pochon C, Martelli H, Mussini C, Pariente D, Heymann MF, Corradini N. J Pediatr Hematol Oncol. 2015 ;37 (5):411-3

Anticancer activity of halofuginone in a preclinical model of osteosarcoma: inhibition of tumor growth and lung metastases. Lamora A, Mullard M, Amiaud J, Brion R, Heymann D, Redini F, Verrecchia F. Oncotarget. 2015;6 (16):14413-27.

BYL719, a new α-specific PI3K inhibitor: single administration and in combination with conventional chemotherapy for the treatment of osteosarcoma. Gobin B, Huin MB, Lamoureux F, Ory B, Charrier C, Lanel R, Battaglia S, Redini F, Lezot F, Blanchard F, Heymann D. Int J Cancer. 2015;136 (4):784-96

Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers. Ségaliny AI, Tellez-Gabriel M, Heymann MF, Heymann D. J Bone Oncol. 2015;4 (1):1-12

Ossifying fibromyxoid tumor (OFMT) - A rare cause of a painful thumb. Sharma K, Hughes D, Harper RD. Int J Surg Case Rep. 2015;7C:93-5

Overexpression of smad7 blocks primary tumor growth and lung metastasis development in osteosarcoma. Lamora A, Talbot J, Bougras G, Amiaud J, Leduc M, Chesneau J, Taurelle J, Stresing V, Le Deley MC, Heymann MF, Heymann D, Redini F, Verrecchia F. Clin Cancer Res. 2014;20 (19):5097-112.

Clusterin inhibition using OGX-011 synergistically enhances zoledronic acid activity in osteosarcoma. Lamoureux F, Baud'huin M, Ory B, Guiho R, Zoubeidi A, Gleave M, Heymann D, Rédini F. Oncotarget. 2014;5 (17):7805-19.

Zoledronic acid inhibits pulmonary metastasis dissemination in a preclinical model of Ewing's sarcoma via inhibition of cell migration. Odri G, Kim PP, Lamoureux F, Charrier C, Battaglia S, Amiaud J, Heymann D, Gouin F, Redini F. BMC Cancer. 2014;14:169.

Imatinib mesylate exerts anti-proliferative effects on osteosarcoma cells and inhibits the tumour growth in immunocompetent murine models. Gobin B, Moriceau G, Ory B, Charrier C, Brion R, Blanchard F, Redini F, Heymann D. PLoS One. 2014;9 (3)

Trophic activity of human P2X7 receptor isoforms A and B in osteosarcoma. Giuliani AL, Colognesi D, Ricco T, Roncato C, Capece M, Amoroso F, Wang QG, De Marchi E, Gartland A, Di Virgilio F & Adinolfi E (2014) PLoS ONE, 9(9).

New chondrosarcoma cell lines and mouse models to study the link between chondrogenesis and chemoresistance. Monderer D, Luseau A, Bellec A, David E, Ponsolle S, Saiagh S, Bercegeay S, Piloquet P, Denis MG, Lodé L, Rédini F, Biger M, Heymann D, Heymann MF, Le Bot R, Gouin F, Blanchard F. Lab Invest. 2013 ;93 (10):1100-14

Drugs targeting the bone microenvironment: new therapeutic tools in Ewing's sarcoma? Redini F, Odri GA, Picarda G, Gaspar N, Heymann MF, Corradini N, Heymann D. Expert Opin Emerg Drugs. 2013;18 (3):339-52

Targeted therapies for bone sarcomas. Heymann D, Rédini F. Bonekey Rep. 2013;2:378

Impact of oncopediatric dosing regimen of zoledronic acid on bone growth: preclinical studies and case report of an osteosarcoma pediatric patient. Battaglia S, Dumoucel S, Chesneau J, Heymann MF, Picarda G, Gouin F, Corradini N, Heymann D, Redini F. J Bone Miner Res. 2011;26(10):2439-51

The Bone Niche of Chondrosarcoma: A Sanctuary for Drug Resistance, Tumour Growth and also a Source of New Therapeutic Targets. David E, Blanchard F, Heymann MF, De Pinieux G, Gouin F, Rédini F, Heymann D. Sarcoma. 2011;2011:932451.

Safety concern between autologous fat graft, mesenchymal stem cell and osteosarcoma recurrence. Perrot P, Rousseau J, Bouffaut AL, Rédini F, Cassagnau E, Deschaseaux F, Heymann MF, Heymann D, Duteille F, Trichet V, Gouin F. PLoS One. 2010 ; 8;5 (6)

• Sarcoma and Angiogenesis

Differential Expression of VEGFA Isoforms Regulates Metastasis and Response to Anti-VEGFA Therapy in Sarcoma. English WR, Lunt SJ, Fisher M, Lefley DV, Dhingra M, Lee YC, Bingham K, Hurrell JE, Lyons SK, Kanthou C, Tozer GM. Cancer Res 2017;77(10):2633-2646.

Measurement of the acute metabolic response to hypoxia in rat tumours in vivo using magnetic resonance spectroscopy and hyperpolarised pyruvate. Bluff JE, Reynolds S, Metcalf S, Alizadeh T, Kazan SM, Bucur A, Wholey EG, Bibby BA, Williams L, Paley MN, Tozer GM. Radiother Oncol. 2015;116(3):392-9.

Angiogenic growth factor expression in benign and malignant vascular tumours. Young RJ, Fernando M, Hughes D, Brown NJ, Woll PJ. Exp Mol Pathol. 2014;97 (1):148-53.

Tumour cells expressing single VEGF isoforms display distinct growth, survival and migration characteristics. Kanthou C, Dachs GU, Lefley DV, Steele AJ, Coralli-Foxon C, Harris S, Greco O, Dos Santos SA, Reyes-Aldasoro CC, English WR, Tozer GM. PLoS One. 2014;9 (8)

Angiogenic growth factor expression in benign and malignant vascular tumours. Young RJ, Fernando M, Hughes D, Brown N, Woll P. Exp Mol Pathol. 2014. 97(1):148-53.

Vascular-targeted agents for the treatment of angiosarcoma. Young RJ, Woll PJ, Staton CA, Reed MWR, Brown NJ. Cancer Chemother & Pharmacol. 2014. 3(2):259-70.

Influence of soluble or matrix-bound isoforms of vascular endothelial growth factor-A on tumor response to vascular-targeted strategies. Akerman S, Fisher M, Daniel RA, Lefley D, Reyes-Aldasoro CC, Lunt SJ, Harris S, Bjorndahl M, Williams LJ, Evans H, Barber PR, Prise VE, Vojnovic B, Kanthou C, Tozer GM. Int J Cancer. 2013;133 (11):2563-76

Kinetic modeling of hyperpolarized (13)C pyruvate metabolism in tumors using a measured arterial input function. Kazan SM, Reynolds S, Kennerley A, Wholey E, Bluff JE, Berwick J, Cunningham VJ, Paley MN, Tozer GM. Magn Reson Med. 2013;70(4):943-53.

Anti-angiogenic therapy: Concept to Clinic. Young RJ, Reed MWR. Microcirculation. 2012.19(2): 115-125.

Anti-angiogenic properties of ADAMTS-4, in vitro. Hsu Y-P, Staton CA, Cross N, Buttle DJ. (2012) Int J Exp Pathol. 93:70-77.

Targeting VEGF in Human Angiosarcoma Cell Lines in Vitro. Young RJ, Woll PJ, Staton CA, Reed MW, Brown NJ. European J Cancer 2011. 47: S665.

Investigation of protein induction in tumour vascular targeted strategies by MALDI MSI. Cole LM, Djidja MC, Bluff J, Claude E, Carolan VA, Paley M, Tozer GM, Clench MR. Methods. 2011;54(4):442-53.

Angiosarcoma. Young RJ, Brown NJ, Reed MW, Hughes D, Woll PJ. Lancet Oncol 2010; 11: 983-91.

Systemic antiangiogenic activity of cationic poly-L-lysine dendrimer delays tumor growth. Al-Jamal KT, Al-Jamal WT, Akerman S, Podesta JE, Yilmazer A, Turton JA, Bianco A, Vargesson N, Kanthou C, Florence AT, Tozer GM, Kostarelos K. Proc Natl Acad Sci U S A. 2010 ;107(9):3966-71.

Estimation of apparent tumor vascular permeability from multiphoton fluorescence microscopic images of P22 rat sarcomas in vivo. Reyes-Aldasoro CC, Wilson I, Prise VE, Barber PR, Ameer-Beg

• Sarcoma and Genetic


Imaging biomarker roadmap for cancer studies. O'Connor JP, Aboagye EO, Adams JE, Aerts HJ, Barrington SF, Beer AJ, Boellaard R, Bohndiek SE, Brady M, Brown G, Buckley DL, Chenevert TL, Clarke LP, Collette S, Cook GJ, deSouza NM, Dickson JC, Dive C, Evelhoch JL, Faivre-Finn C, Gallagher FA, Gilbert FJ, Gillies RJ, Goh V, Griffiths JR, Groves AM, Halligan S, Harris AL, Hawkes DJ, Hoekstra OS, Huang EP, Hutton BF, Jackson EF, Jayson GC, Jones A, Koh DM, Lacombe D, Lambin P, Lassau N, Leach MO, Lee TY, Leen EL, Lewis JS, Liu Y, Lythgoe MF, Manoharan P, Maxwell RJ, Miles KA, Morgan B, Morris S, Ng T, Padhani AR, Parker GJ, Partridge M, Pathak AP, Peet AC, Punwani S, Reynolds AR, Robinson SP, Shankar LK, Sharma RA, Soloviev D, Stroobants S, Sullivan DC, Taylor SA, Tofts PS, Tozer GM, van Herk M, Walker-Samuel S, Wason J, Williams KJ, Workman P, Yankeelov TE, Brindle KM, McShane LM, Jackson A, Waterton JC. Nat Rev Clin Oncol. 2017;14(3):169-186.

• Sarcoma and Clinical Trials


Immobilization and image-guidance methods for radiation therapy of limb extremity soft tissue sarcomas: Results of a multi-institutional survey. Swinscoe JA, Dickie CI, Ireland RH. Med Dosim. In press

Spindle cell sarcoma of the mitral valve: a rare indication for mitral valve replacement. Massey JNR, Suvarna SK, Krawczyk K, Hunter S. Eur J Cardiothorac Surg. 2018 ;53(3):682-683.


Predictive and prognostic factors associated with soft tissue sarcoma response to chemotherapy: a subgroup analysis of the European Organisation for Research and Treatment of Cancer 62012 study. Young RJ, Litière S, Lia M, Hogendoorn PCW, Fisher C, Mechtersheimer G, Daugaard S, Sciot R, Collin F, Messiou C, Grünwald V, Gronchi A, van der Graaf W, Wardelmann E, Judson I. Acta Oncol. 2017;56(7):1013-1020.

Anti-angiogenic therapies for the treatment of angiosarcoma: a clinical update. Young RJ, Woll PJ. Memo. 2017;10(4):190-193.

Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial. Seddon B, Strauss SJ, Whelan J, Leahy M, Woll PJ, Cowie F, Rothermundt C, Wood Z, Benson C, Ali N, Marples M, Veal GJ, Jamieson D, Küver K, Tirabosco R, Forsyth S, Nash S, Dehbi HM, Beare S. Lancet Oncol. 2017 Oct;18(10):1397-1410.


High quality genomic copy number data from archival formalin-fixed paraffin-embedded leiomyosarcoma: optimisation of universal linkage system labelling. Salawu A, Ul-Hassan A, Hammond D, Fernando M, Reed M, Sisley K. PLoS One. 2012;7 (11)

Common genetic changes in leiomyosarcoma and gastrointestinal stromal tumour: implication for ataxia telangiectasia mutated involvement. Ul-Hassan A, Sisley K, Hughes D, Hammond DW, Robinson MH, Reed MW. Int J Exp Pathol. 2009 ;90(5):549-57.

Absence of progression, not extent of tumour shrinkage, defines prognosis in soft-tissue sarcoma - An analysis of the EORTC 62012 study of the EORTC STBSG. Grünwald V, Litière S, Young R, Messiou C, Lia M, Wardelmann E, van der Graaf W, Gronchi A, Judson I; EORTC STBSG. Eur J Cancer. 2016;64:44-51

Eribulin in soft-tissue sarcoma. Young RJ, Woll PJ. Lancet. 2016;387(10028):1594-6.


A UK national phase I/II clinical trial of a MEK1/2 inhibitor combined with highly active anti-retroviral therapy for HIV-associated Kaposi’s sarcoma. Young R, Poyser C, Crack L, Dockrell D, Bowman C, Billlingham L, Bower M, Westwell S, Leahy M, Woll P. Eur J Cancer. 2015. 51:S699.

Absence of progression, not extent of remission defines prognosis in soft tissue sarcoma – an analysis of the EORTC 62012 study. Grünwald V, Litiere S, Young RJ, Messiou C, Michela L, Wardelmann E, Van der Graaf W, Gronchi A, Judson I. Eur J Cancer. 2015. 51:S688. First-line anthracycline-based chemotherapy for angiosarcoma and other soft tissue sarcoma subtypes: pooled analysis of eleven EORTC Soft Tissue and Bone Sarcoma Group trials. Eur J Cancer.Young RJ, Natukunda A, Litiere S, Woll PJ, Wardelmann E, van der Graaf WTA. 2014 ; 50(18):3178-86.

Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. Woll PJ, Reichardt P, Le Cesne A, Bonvalot S, Azzarelli A, Hoekstra HJ, Leahy M, Van Coevorden F, Verweij J, Hogendoorn PC, Ouali M, Marreaud S, Bramwell VH, Hohenberger P; EORTC Soft Tissue and Bone Sarcoma Group and the NCIC Clinical Trials Group Sarcoma Disease Site Committee. Lancet Oncol. 2012 Oct;13 (10):1045-54.

Zoledronic acid to prevent and treat cancer metastasis: new prospects for an old drug. Young RJ, Coleman RE. Future Oncol. 2013. 9(5): 633-43.

Analysis of circulating angiogenic biomarkers from patients in two phase III trials in lung cancer of chemotherapy alone or chemotherapy and thalidomide. Young RJ*, Tin AW*, Brown NJ, Jitlal M, Lee SM, Woll PJ. Br J Cancer. 2012. 106(6): 1153-1159.